Viking Therapeutics, Inc.
VKTX
Pozycja w akcjach
#4539
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Cena akcji
$26.41
Kapitalizacja rynkowa
$3.36B
Zmiana (1 dzień)
-1.12%
Zmiana (1 rok)
-19.92%
Kraj
US
Handel Viking Therapeutics, Inc. (VKTX)
Kategoria
Healthcare
Zyski dla Viking Therapeutics, Inc. (VKTX)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Viking Therapeutics, Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Viking Therapeutics, Inc. od 2026 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| Za mało danych dla podanych dat. | ||
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
